Acute Pancreatitis - Pipeline Insight, 2024

This “Acute Pancreatitis - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Acute Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Pancreatitis: Understanding

Acute Pancreatitis: Overview

Acute pancreatitis is a significant disease that leads to hospitalization among gastrointestinal disorders in the United States, characterized by the acute inflammation of the pancreas. The severity of acute pancreatitis varies widely, ranging from mild cases that require conservative treatment to severe and complicated forms with high morbidity and mortality rates. Mortality rates can range from 3% in mild edematous pancreatitis to as high as 20% in cases with pancreatic necrosis. The Atlanta classification categorizes acute pancreatitis into two main types: interstitial edematous pancreatitis, involving inflammation of the pancreatic parenchyma and surrounding tissues, and necrotizing pancreatitis, characterized by necrosis of the pancreatic tissue and surrounding areas. Based on disease severity, acute pancreatitis is further classified into mild, moderately severe, and severe forms, with varying levels of organ failure and complications. Early and accurate diagnosis is crucial, but predicting the disease progression and outcome remains a challenge, highlighting the importance of timely and appropriate care for patients with acute pancreatitis.

Acute pancreatitis manifests with various signs and symptoms, typically characterized by sudden and severe pain in the upper abdomen that can radiate to the back, often exacerbated after eating and relieved by leaning forward. Nausea, vomiting, fever, rapid pulse, and a tender abdomen are common accompanying symptoms. In some cases, individuals may experience a high temperature, sweating, and a general feeling of being unwell. The pain associated with acute pancreatitis can be intense and may require immediate medical attention. It is essential to seek prompt medical care if experiencing severe abdominal pain, especially if accompanied by other symptoms like vomiting, fever, or jaundice, as these could indicate serious complications requiring urgent treatment.

Treatment and management of acute pancreatitis involve a multifaceted approach tailored to the severity and underlying cause of the condition. Initially, resuscitation with intravenous fluids, analgesics, and antiemetics is crucial even before a definitive diagnosis is made. For mild cases, patients are kept nothing by mouth and receive intravenous fluid hydration, analgesics for pain relief, and early enteral feeding once symptoms improve. In cases of gallstone-induced pancreatitis, early cholecystectomy is recommended, while alcohol-induced cases necessitate addressing alcohol dependency with the help of a chemical dependency counselor. Severe cases may require management in a high-dependency unit or intensive care unit, with broad-spectrum antibiotics considered for prophylaxis against infection in confirmed pancreatic necrosis. Monitoring for complications like systemic issues (e.g., disseminated intravascular coagulation, acute respiratory distress syndrome) and local complications (e.g., pancreatic necrosis) is essential, with imaging studies like CT scans used to guide treatment decisions. Overall, supportive care, treating the underlying cause, and close monitoring are key components of managing acute pancreatitis effectively.

"Acute Pancreatitis - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pancreatitis pipeline landscape is provided which includes the disease overview and Acute Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Acute Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve Acute Pancreatitis.

Acute Pancreatitis Emerging Drugs Chapters

This segment of the Acute Pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Pancreatitis Emerging Drugs

CM-4620: CalciMedica

CalciMedica’s lead product candidate, CM4620, is a proprietary intravenous-formulated CRAC channel inhibitor, is being developed for several indications including the treatment of respiratory distress syndrome associated with COVID-19, acute respiratory distress syndrome (ARDS) due to other types of pneumonia, predicted severe acute pancreatitis and other acute inflammatory diseases associated with dysregulation of intracellular calcium in organ tissues like the lung, pancreas or kidneys. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Acute Pancreatitis.

Acute Pancreatitis: Therapeutic Assessment

This segment of the report provides insights about the different Acute Pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Pancreatitis

There are approx. 4+ key companies which are developing the therapies for Acute Pancreatitis. The companies which have their Acute Pancreatitis drug candidates in the most advanced stage, i.e. Phase II include, CalciMedica.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Pancreatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Pancreatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Pancreatitis drugs.

Acute Pancreatitis Report Insights

• Acute Pancreatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Pancreatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Pancreatitis drugs?
• How many Acute Pancreatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Pancreatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Pancreatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Pancreatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CalciMedica
• SCM Lifescience
• Lamassu Pharma

Key Products

• CM-4620
• SCM-AGH
• RABI-767

Please note: The report will be dispatched within 2-3 days